| NASDAQ (usa) |
 |
6715.56 | -12.11 | -0.18% |
| FTSE 100 (london) |
|
7487.96 | -5.12 | -0.07% |
| DAX (german) |
 |
13465.51 | 235.94 | 1.78% |
| NIKKEI 225 (japan) |
|
22420.08 | 408.47 | 1.86% |
| Hang - Seng (hong kong) |
|
28594.06 | 348.52 | 1.23% |
| NIFTY - 50 (india) | ||||
| Straits Times (singapore) |
|
3391.61 | 17.53 | 0.52% |
| KOSPI (korea) |
|
2556.47 | 33.04 | 1.31% |
| All Ordinaries (australia) |
|
6005.30 | 28.90 | 0.48% |
| BOVESPA (brazil) |
|
74092.76 | -215.73 | -0.29% |
Natco Pharma Limited (NSE: NATCOPHARM)
NATCOPHARM Technical Analysis
4
| As on 24th Apr 2024 NATCOPHARM SHARE Price closed @ 998.60 and we RECOMMEND Strong Buy for LONG-TERM with Stoploss of 824.62 & Buy for SHORT-TERM with Stoploss of 966.57 we also expect STOCK to react on Following IMPORTANT LEVELS. |
NATCOPHARMSHARE Price
| Open | 1028.00 | Change | Price | % |
| High | 1031.00 | 1 Day | -24.20 | -2.37 |
| Low | 995.80 | 1 Week | 11.70 | 1.19 |
| Close | 998.60 | 1 Month | 46.55 | 4.89 |
| Volume | 367850 | 1 Year | 429.70 | 75.53 |
| 52 Week High 913.65 | 52 Week Low 523.90 | ||||
NSE INDIA Most Active Stocks
| IDEA | 13.10 | -9.03% |
| SAIL | 164.65 | 8.14% |
| YESBANK | 25.45 | -0.78% |
| TATASTEEL | 165.55 | 2.73% |
| IRFC | 149.00 | 0.85% |
| SOUTHBANK | 29.10 | 1.04% |
| MRPL | 248.70 | 10.75% |
| SUZLON | 41.80 | -0.12% |
| BEL | 236.50 | 0.92% |
| RAMASTEEL | 14.00 | 2.56% |
NSE INDIA Top Gainers Stocks
| ROML | 63.05 | 19.98% |
| COMPUSOFT | 35.20 | 19.93% |
| SHRADHA | 78.55 | 19.83% |
| STEELCITY | 102.95 | 19.78% |
| WEIZMANIND | 142.25 | 19.59% |
| TEMBO | 240.90 | 18.61% |
| CHENNPETRO | 1075.00 | 15.82% |
| YUKEN | 1180.65 | 13.81% |
| ORIENTCEM | 230.50 | 12.85% |
| AEGISCHEM | 604.50 | 12.41% |
NSE INDIA Top Losers Stocks
| NATCOPHARM Daily Charts |
NATCOPHARM Intraday Charts |
Whats New @ Bazaartrend |
NATCOPHARM Free Analysis |
|
|
NATCOPHARM Important Levels Intraday
| RESISTANCE | 1066.43 |
| RESISTANCE | 1044.68 |
| RESISTANCE | 1031.23 |
| RESISTANCE | 1017.78 |
| SUPPORT | 979.42 |
| SUPPORT | 965.97 |
| SUPPORT | 952.52 |
| SUPPORT | 930.77 |
NATCOPHARM Target April 2024
| 4th UP Target | 1567.31 |
| 3rd UP Target | 1379.84 |
| 2nd UP Target | 1263.96 |
| 1st UP Target | 1148.08 |
| 1st DOWN Target | 817.42 |
| 2nd DOWN Target | 701.54 |
| 3rd DOWN Target | 585.66 |
| 4th DOWN Target | 398.19 |
NATCOPHARM Weekly Target
| 4th UP Target | 1125.04 |
| 3rd UP Target | 1084.75 |
| 2nd UP Target | 1059.84 |
| 1st UP Target | 1034.93 |
| 1st DOWN Target | 963.87 |
| 2nd DOWN Target | 938.96 |
| 3rd DOWN Target | 914.05 |
| 4th DOWN Target | 873.76 |
NATCOPHARM Target2024
| 4th UP Target | 1632.25 |
| 3rd UP Target | 1368.98 |
| 2nd UP Target | 1206.25 |
| 1st UP Target | 1043.52 |
| 1st DOWN Target | 579.18 |
| 2nd DOWN Target | 416.45 |
| 3rd DOWN Target | 253.72 |
| 4th DOWN Target | -9.55 |
Natco Pharma Limited ( NSE INDIA Symbol : NATCOPHARM )
Sector : Healthcare And Other Stocks in Same Sector
Sector : Healthcare And Other Stocks in Same Sector
NATCOPHARM Synopsis Technicals View
| 50 Day EMA |
Close is Above EMA 50 (Short Term) |
Bullish | |
| 100 Day EMA | Close is Above EMA 100 (Mid Term) | Bullish | |
| 200 Day EMA | Close is Above EMA 200 (Long Term) | Bullish | |
| MACD (12 26 9) | MACD Line is Less Then SIGNAL Line | Bearish | |
| RSI (14) | RSI is Below 30 | Over Sold | |
| MFI (14) | MFI is 30.47 | Sideways | |
| CCI (20) | CCI is Below -100 | Over Sold | |
| WILLIAM %R (14) | William %R is -62.24 | Sideways | |
| ADX (14) | ADX is Above 20 & +DI is Below -DI | Down Trend | |
| PSAR | Stoploss For Long Buy | 570.80 | |
| 10 Day Avg Volume | Traded -20.22 % Less then 10 Day Average Volume | ||
NATCOPHARM Other Details
| Segment | EQ | |
| Market Capital | 151340548096.00 | |
| Sector | Healthcare | |
| Industry | Drug Manufacturers-Specialty & Generic | |
| Offical website | > | |
NATCOPHARM Address
 |
||
NATCOPHARM Latest News
NATCOPHARM Business Profile
NATCO Pharma Limited, a pharmaceutical company, develops, manufactures, and markets finished dosage formulations and active pharmaceutical ingredients (APIs). It offers formulations in various therapeutic areas, including cancers of blood, liver, kidney, lung, brain, breast, ovary, etc.; and APIs in various categories, such as oncology, central nervous system, pain management, and CV care. The company also offers orthopedic products comprising bisphosphonates, which are oral and injectable drugs; and gastroenterology products consisting of novel drugs for chronic hepatitis-B and hepatitis-C, as well as contract manufacturing services. In addition, it provides cardiology and diabetology products for the treatment of hypertension, stable angina and CHF. The company markets its products in approximately 40 countries, including India, the United States, and internationally. NATCO Pharma Limited was incorporated in 1981 and is headquartered in Hyderabad, India. Address: NATCO House, Hyderabad, India, 500034
© 2005-2023 BazaarTrend.com All rights reserved.
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service